Clinical Diagnosis and Treatment Recommendations for Immune Checkpoint Inhibitor-related Hematological Adverse Events.
10.3779/j.issn.1009-3419.2019.10.13
- Author:
Junling ZHUANG
1
;
Jingting ZHAO
1
;
Xiaoxiao GUO
2
;
Jiaxin ZHOU
3
;
Lian DUAN
4
;
Wei QIU
5
;
Xiaoyan SI
6
;
Li ZHANG
7
;
Yue LI
8
;
Xiaowei LIU
9
;
Hanping WANG
6
;
Daobin ZHOU
1
;
Li ZHANG
6
Author Information
1. Department of Hemotology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
2. Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
3. Department of Rheumatology and Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
4. Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
5. Department of Nephrology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
6. Department of Respirology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
7. Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
8. Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
9. Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing 100730, China.
- Publication Type:Journal Article
- Keywords:
Cytopenia;
Immune checkpoint inhibitor;
Immune-related adverse events
- From:
Chinese Journal of Lung Cancer
2019;22(10):676-680
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors are able to reactivate the immune system therefore enhance the anti-tumor effects. However, over-activated T cells may induce immune related adverse events (irAEs). Hematological irAEs are rarely reported, which mainly represent as mono-lineage cytopenia or pancytopenia, including autoimmune hemolytic anemia (AIHA), immune thrombocytopenia (ITP), neutropenia and aplastic anemia, sometimes even lethal, such as hemophagocytic lymphohistiocytosis. The clinical manifestations of hematological irAEs will be summarized and recommendations of diagnosis and treatment are proposed.
